Zacks Research Forecasts Higher Earnings for Globus Medical

Key Points

• Zacks Research raised Globus Medical’s Q3 2026 EPS forecast to $1.18 from $1.16 and maintains a “Strong Buy” rating. Full-year 2026 estimates are approximately $4.97–$4.99 per share.
• Globus Medical’s latest quarterly results exceeded expectations, with EPS of $1.34 versus the $1.10 consensus and revenue of $789.6 million, up 5.9% year over year. Management reaffirmed FY 2026 EPS guidance of $4.95–$5.05.
• Shares opened at $82.57, while analysts’ consensus rating remains “Moderate Buy” with a $101.77 target price; institutional investors own 95.16% of the stock, though two directors recently sold shares.

Globus Medical, Inc. (NYSE:GMED - Free Report) - Equities research analysts at Zacks Research upped their Q3 2026 earnings per share estimates for Globus Medical in a note issued to investors on Thursday, August 27th. Zacks Research analyst Team now forecasts that the medical device company will earn $1.18 per share for the quarter, up from their previous estimate of $1.16. Zacks Research has a "Strong-Buy" rating on the stock. The consensus estimate for Globus Medical's current full-year earnings is $4.99 per share. Zacks Research also issued estimates for Globus Medical's FY2026 earnings at $4.97 EPS, Q1 2027 earnings at $1.13 EPS, Q2 2027 earnings at $1.33 EPS, Q3 2027 earnings at $1.24 EPS, FY2027 earnings at $5.06 EPS, Q1 2028 earnings at $1.38 EPS and Q2 2028 earnings at $1.46 EPS.

Several other analysts have also issued reports on GMED. Piper Sandler dropped their price target on shares of Globus Medical from $115.00 to $100.00 and set an "overweight" rating on the stock in a research report on Monday, June 15th. UBS Group started coverage on shares of Globus Medical in a research report on Tuesday, July 28th. They issued a "neutral" rating and a $82.00 price objective for the company. Stifel Nicolaus lowered their price objective on shares of Globus Medical from $95.00 to $80.00 and set a "hold" rating on the stock in a research note on Wednesday, July 8th. Royal Bank Of Canada dropped their target price on shares of Globus Medical from $120.00 to $115.00 and set an "outperform" rating on the stock in a report on Monday, July 13th. Finally, Wall Street Zen downgraded shares of Globus Medical from a "strong-buy" rating to a "buy" rating in a research note on Saturday, May 9th. Three analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and five have assigned a Hold rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $101.77.

Globus Medical Trading Down 0.6%

NYSE GMED opened at $82.57 on Friday. Globus Medical has a 12 month low of $54.15 and a 12 month high of $101.40. The stock has a 50 day moving average of $81.05 and a 200-day moving average of $84.63. The company has a market cap of $11.09 billion, a PE ratio of 21.12, a PEG ratio of 1.34 and a beta of 0.95.

Globus Medical (NYSE:GMED - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The medical device company reported $1.34 earnings per share for the quarter, beating analysts' consensus estimates of $1.10 by $0.24. Globus Medical had a return on equity of 14.57% and a net margin of 17.02%.The firm had revenue of $789.61 million during the quarter, compared to the consensus estimate of $782.88 million. During the same period last year, the company earned $0.86 earnings per share. The business's revenue was up 5.9% compared to the same quarter last year. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Northwestern Mutual Wealth Management Co. increased its stake in shares of Globus Medical by 71,618.6% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 716,469 shares of the medical device company's stock worth $62,555,000 after purchasing an additional 715,470 shares during the period. WCM Investment Management LLC acquired a new stake in Globus Medical during the 1st quarter worth approximately $16,965,000. SG Americas Securities LLC boosted its stake in Globus Medical by 241.1% in the 1st quarter. SG Americas Securities LLC now owns 340,452 shares of the medical device company's stock valued at $29,333,000 after purchasing an additional 240,642 shares during the period. Hyperion Capital Advisors LP bought a new stake in Globus Medical in the 4th quarter valued at $12,822,000. Finally, Hsbc Holdings PLC bought a new stake in Globus Medical in the 4th quarter valued at $2,254,000. Institutional investors and hedge funds own 95.16% of the company's stock.

Insiders Place Their Bets

In other news, Director Stephen T. Zarrilli sold 25,000 shares of the stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $87.04, for a total value of $2,176,000.00. Following the transaction, the director directly owned 25,000 shares of the company's stock, valued at $2,176,000. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director David D. Davidar sold 25,000 shares of the firm's stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $80.76, for a total transaction of $2,019,000.00. Following the sale, the director owned 510,175 shares of the company's stock, valued at approximately $41,201,733. This represents a 4.67% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 18.38% of the company's stock.

Globus Medical Company Profile

Globus Medical, Inc NYSE: GMED is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source